Gameto – Weekly Recap

Gameto is a women’s health biotech focused on fertility treatments, and this weekly recap highlights notable progress in its late-stage clinical program. Over the past week, the company announced the expansion of its Phase III Fertilo trial in the U.S., marking a meaningful operational milestone.

Gameto added Columbia University Fertility Center in New York as a new trial site for Fertilo, according to its recent LinkedIn updates. The center, led by Dr. Eric Forman, was ranked the top fertility clinic in Newsweek’s 2025 America’s Best Fertility Clinics and is currently the only New York site participating in the study.

The inclusion of this highly ranked academic center appears to expand geographic access for eligible New York patients, who may be able to participate in the trial with covered cycles. This broader access could support stronger and more diverse patient enrollment, which is important for generating robust Phase III data.

The company’s communications also note that multiple sites across the country are already participating and that additional locations are expected. This growing clinical network may enhance trial visibility among key opinion leaders and reinforce Gameto’s presence in the IVF and women’s health markets.

From a strategic perspective, expansion into a leading New York fertility center may strengthen the evidentiary and commercial foundation for Fertilo, assuming favorable clinical outcomes. It could also improve Gameto’s positioning for future regulatory submissions and potential partnerships in the reproductive medicine space.

Overall, the week underscored steady momentum for Gameto’s Fertilo program, with the Columbia University Fertility Center addition signaling continued scale-up of its Phase III trial and broader engagement with top-tier fertility clinics.